Protected forms of pharmacologically active agents and uses...

Details Protected forms of pharmacologically active agents and uses... Protected forms of pharmacologically active agents and uses...

2000-06-23

2002-03-12

Higel, Floyd D. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S415000, C514S424000, C514S517000, C514S532000, C514S533000, C514S534000, C548S366700, C548S367100, C548S449000, C548S486000, C558S052000, C558S062000, C560S060000, C560S073000, C564S092000, C564S167000, C564S168000

Reexamination Certificate

active

06355666

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to novel forms of pharmacologically active agents, and methods for the preparation and use thereof. In a particular aspect of the invention, methods are provided for treating pathological conditions with a protected form of one or more pharmacologically active agents, thereby reducing the occurrence of side-effects caused thereby.
BACKGROUND OF THE INVENTION
Despite the advent of modem pharmaceutical technology, many drugs still possess untoward toxicities which often limit the therapeutic potential thereof. For example, although non-steroid anti-inflammatory drugs (NSAIDs) are a class of compounds which are widely used for the treatment of inflammation, pain and fever, NSAIDs (e.g., naproxen, aspirin, ibuprofen and ketoprofen) can cause gastrointestinal ulcers, a side-effect that remains the major limitation to the use of NSAIDs (see, for example, J. L. Wallace, in Gastroenterol. 112:1000-1016 (1997); A. H. Soll et al., in Ann Intern Med. 114:307-319 (1991); and J. Bjarnason et al., in Gastroenterol. 104:1832-1847 (1993)).
There are two major ulcerogenic effects of NSAIDs: (1) irritant effects on the epithelium of the gastrointestinal tract and (2) suppression of gastrointestinal prostaglandin synthesis. In recent years, numerous strategies have been attempted to design and develop new NSAIDs that reduce the damage to the gastrointestinal tract. These efforts, however, have largely been unsuccessful. For example, enteric coating or slow-release formulations designed to reduce the topical irritant properties of NSAIDs have been shown to be ineffective in terms of reducing the incidence of clinically significant side effects, including perforation and bleeding (see, for example, D. Y. Graham et al., in Clin. Pharmacol. Ther. 38:65-70 (1985); and J. L. Carson, et al., in Arch. Intern. Med., 147:1054-1059 (1987)).
It is well recognized that aspirin and other NSAIDs exert their pharmacological effects through the non-selective inhibition of cyclooxygenase (COX) enzymes, thereby blocking prostaglandin synthesis (see, for example, J. R. Van in Nature, 231:232-235 (1971)). There are two types of COX enzymes, namely COX-1 and COX-2. COX-1 is expressed constitutively in many tissues, including the stomach, kidney, and platelets, whereas COX-2 is expressed only at the site of inflammation (see, for example, S. Kargan et al. in Gastroenterol., 111:445-454 (1996)). The prostagladins derived from COX-1 are responsible for many of the physiological effects, including maintenance of gastric mucosal integrity.
Many attempts have been made to develop NSAIDs that only inhibit COX-2, without impacting the activity of COX-1 (see, for example, J. A. Mitchell et al., in Proc. Natl. Acad. Sci. USA 90:11693-11697 (1993); and E. A. Meade et al., in J. Biol. Chem., 268:6610-6614 (1993)). There are several NSAIDs presently on the market (e.g., rofecoxib and celecoxib) that show marked selectivity for COX-2 (see, for example, E. A. Meade, supra.; K. Glaser et al., in Eur. J. Pharmacol. 281:107-111 (1995) and Kaplan-Machlis, B., and Klostermeyer, BS in Ann Pharmacother. 33:979-88, (1999)). These drugs appear to have reduced gastrointestinal toxicity relative to other NSAIDs on the market.
On the basis of encouraging clinical as well as experimental data, the development of highly selective COX-2 inhibitors appears to be a sound strategy to develop a new generation of anti-inflammatory drugs. However, the physiological functions of COX-1 and COX-2 are not always well defined. Thus, there is a possibility that prostagladins produced as a result of COX-1 expression may also contribute to inflammation, pain and fever. On the other hand, prostagladins produced by COX-2 have been shown to play important physiological functions, including the initiation and maintenance of labor and in the regulation of bone resorption (see, for example, D. M. Slater et al., in Am. J. Obstet. Gynecol., 172:77-82 (1995); and Y. Onoe et al., in J. Immunol. 156:758-764 (1996)), thus inhibition of this pathway may not always be beneficial. Considering these points, highly selective COX-2 inhibitors may produce additional side effects above and beyond those observed with standard NSAIDs, therefore such inhibitors may not be highly desirable.
Accordingly, there is still a need in the art for modified forms of NSAIDs which cause a reduced incidence of side-effects, relative to the incidence of side-effects caused by such pharmacologically active agents in unmodified form.
BRIEF DESCRIPTION OF THE INVENTION
In accordance with the present invention, there is provided a new class of modified NSAIDs which cause a much lower incidence of side-effects than are typically observed with unmodified NSAIDs due to the protective effects imparted by modifying the NSAIDs as described herein.
There are a number of advantages provided by modified NSAIDs according to the invention including:
(i) reduced irritant effects (e.g., contact irritation) of NSAIDs, and
(ii) enhanced tissue delivery of the drug as a result of a decrease in net charges on the molecule, particularly for acidic NSAIDs such as naproxen, aspirin, diclofenac and ibuprofen, thereby reducing the quantity of material which must be delivered to achieve an effective dosage.
In accordance with the present invention, cleavage of the modified NSAIDs described herein from the modified group appended thereto releases the pharmaceutically active agent.


REFERENCES:
patent: 6177466 (2001-01-01), Sakaki et al.
Bjarnason, I et al., “Side Effects of Nonsteroidal Anti-inflammatory Drugs on the Small and Large Intestine in Humans”,Special Reports and Reviews, Gastroenterology,104:1832-1847 (1993).
Carson, J.L. et al, “The Relative Gastrointestinal Toxicity of the Nonsteroidal Anti-inflammatory Drugs”,Arch Intern Med,vol. 147, Jun. (1987).
Glaser, K. et al, “Etodolac Selectively Inhibits Human Prostaglandin G/H Synthase 2 (PGHS-2) Versus Human PGHS-1”,European Journal of Pharmacology281, 107-111, (1995).
Graham, D.Y., MD., et al, “Nonsteroidal Anti-inflammatory Effect of Sulindac Sulfoxide and Sulfide on Gastric Mucosa”,Clin Pharmacol Ther,38: 65-70, (1985).
Kaplan-Machlis, B. et al., “The Cyclooxygenase-2 Inhibitors: Safety and Effectiveness”,The Annals of Pharmacotheraphy,vol. 33, 979-88, Sep. (1999).
Kargman, S., et al., “Characterization of Prostaglandin G/H Synthase 1 and 2 in Rat, Dog, Monkey, and Human Gastrointestinal Tracts”,Gastroenterology,American Gastroenterological Association, 111: 445-454, (1996).
Meade, E.A., et al., “Differential Inhibition of Prostaglandin Endoperoxide Synthase (Cyclooxygenase) Isozymes by Aspirin and Other Non-steroidal Anti-inflammatory Drugs”,The Journal of Biological Chemistry,The American Society for Biochemistry and Molecular Biology, Inc., vol. 268, No. 9, 6610-6614, Mar 25 (1993).
Mitchell, J.A., et al., “Selectivity of Nonsteroidal Antiinflammatory Drugs as Inhibitors of Constitutive and Inducible Cyclooxygenase”,Proc. Natl. Acad. Sci. USA,Pharmacology, vol. 90, 11693-11697, Dec. (1994).
Onoe, Y, et al., “IL-13 and IL-4 Inhibit Bone Resorption by Suppressing Cyclooxygenase-2-Dependent Prostaglandin Synthesis in Osteoblasts”,The Journal of Immunology,The American Association of Immunologists, 156: 758-764, (1996).
Slater, D.M., et al. , “Expression of Cyclooxygenase Types 1 and 2 in Human Fetal Membranes at Term”,Am J Obstet Gynecol,vol. 172, No. 1, Part 1, 172: 77-82 (1995).
Soll, A.H., MD, et al., “Nonsteroidal Anti-inflmmatory Drugs and Peptic Ulcer Disease”,Annals of Internal Medicine(UCLA Conference), 114: 307-319, (1991).
Wallace, J.L. “Nonsteroidal Anti-inflammatory Drugs and Gastroenteropathy: The Second Hundred Years”,Gastroenterology,The American Gastroenterological Association, 112: 1000-1016, (1997).

Affiliated with

Also associated with

Rating

Protected forms of pharmacologically active agents and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protected forms of pharmacologically active agents and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protected forms of pharmacologically active agents and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2884291